Comparative Combinatorial Implications and Theranostics of Immunotherapy in
the Impediment of Alveolar Soft Part Sarcoma

Ya      Yang; Narasimha   M.   Beeraka; Junqi      Liu; Xiaoxiao      Zuo; Xin      Wang; Tingxuan      Li; Ruitai      Fan

doi:10.2174/1381612828666220921151750

Abstract

Background: Immune checkpoint inhibitors (ICIs), specifically programmed cell death receptor- 1/ligand 1 (PD-1/L1) inhibitors, have shown potential pharmacological efficacy in several cancers. Nonetheless, data pertinent to their therapeutic efficacy in alveolar soft-part sarcoma (ASPS) are limited.

Objective: The retrospective aspects of ICIs (anti-PD1/PD-L1 blockers) to target ASPS are comparatively analyzed for clinical outcomes with other targeted immunotherapy modalities.

Methods: We have conducted a systematic review without statistical analysis or comprehensive meta-analysis by collecting the articles published between 1952 and Sep 10th, 2020, by searching the following words: alveolar soft part sarcoma and immunotherapy including immune checkpoint, immune checkpoint inhibitors, and PD-1, PD-L1. We performed a pooled analysis of case reports, conferences, clinical trials, and other research reports pertinent to the efficacy of a PD-1 or PD-L1 antagonist in patients diagnosed with metastatic ASPS.

Results: The effective studies include 10 case reports, 2 conference reports, 5 clinical trials, and 2 additional research reports. A total of 110 patients were reported to be enrolled in the pooled analysis; among them, 87 (78.38%) received a PD-1/PD-L1 antagonist. For patients who received anti-PD-1/PD-L1as monotherapy, their clinical response rates (CRR) were 63.22% whereas those who received targeted therapy and immunotherapy had a CRR of 78.95% (15/19). In the patients treated with double immunotherapy, their CRR was 100% (4/4). Tumor mutational burden and mismatch repair status have significant implications for predicting the ASPS prognosis.

Conclusion: Alveolar soft-part sarcoma patients with distant metastases can exhibit better clinical outcomes with immunotherapy, particularly toripalimab, atezolizumab, and axitinib combinatorial regimen with pembrolizumab. In addition, this review describes the therapeutic implications to guide personalized medicine depending on the expression patterns of PD-1/PD-L1 during the immunotherapy with ASPS.

Keywords: Alveolar soft-part sarcoma, immune checkpoint inhibitors (ICIs), PD-L1/PD-1 biomarkers

« Previous

[1]
Penel N, Coindre JM, Giraud A, et al. Presentation and outcome of frequent and rare sarcoma histologic subtypes: A study of 10,262 patients with localized visceral/soft tissue sarcoma managed in reference centers. Cancer  2018; 124(6): 1179-87.
 [http://dx.doi.org/10.1002/cncr.31176] [PMID:  29211310]

[2]
Christopherson WM, Foote FW Jr, Stewart FW. Alveolar soft-part sarcomas. Structurally characteristic tumors of uncertain histogenesis. Cancer  1952; 5(1): 100-11.
 [http://dx.doi.org/10.1002/1097-0142(195201)5:1<100:AID-CNCR2820050112>3.0.CO;2-K] [PMID:  14886902]

[3]
Orbach D, Brennan B, Casanova M, et al. Paediatric and adolescent alveolar soft part sarcoma: A joint series from European cooperative groups. Pediatr Blood Cancer  2013; 60(11): 1826-32.
 [http://dx.doi.org/10.1002/pbc.24683] [PMID:  23857870]

[4]
Randazzo MJ, Thawani JP, Manur R, Brooks JS, Ozturk AK. Metastatic alveolar soft part sarcoma of the spinal cord: A case report and review of literature. World Neurosurg  2017; 103: 953.e1-5.
 [http://dx.doi.org/10.1016/j.wneu.2017.04.100] [PMID:  28450230]

[5]
Lieberman PH, Brennan MF, Kimmel M, Erlandson RA, Garin-Chesa P, Flehinger BY. Alveolar soft-part sarcoma. A clinico-pathologic study of half a century. Cancer  1989; 63(1): 1-13.
 [http://dx.doi.org/10.1002/1097-0142(19890101)63:1<1:AID-CNCR2820630102>3.0.CO;2-E] [PMID:  2642727]

[6]
Portera CA Jr, Ho V, Patel SR, et al. Alveolar soft part sarcoma. Cancer  2001; 91(3): 585-91.
 [http://dx.doi.org/10.1002/1097-0142(20010201)91:3<585:AID-CNCR1038>3.0.CO;2-0] [PMID:  11169942]

[7]
Flores RJ, Harrison DJ, Federman NC, et al. Alveolar soft part sarcoma in children and young adults: A report of 69 cases. Pediatr Blood Cancer  2018; 65(5): e26953.
 [http://dx.doi.org/10.1002/pbc.26953] [PMID:  29350467]

[8]
Jaber OI, Kirby PA. Alveolar soft part sarcoma. Arch Pathol Lab Med  2015; 139(11): 1459-62.
 [http://dx.doi.org/10.5858/arpa.2014-0385-RS] [PMID:  26516944]

[9]
Soheilifar MH, Taheri RA, Zolfaghari Emameh R, Moshtaghian A, Kooshki H, Motie MR. Molecular landscape in alveolar soft part sarcoma: Implications for molecular targeted therapy. Biomed Pharmacother  2018; 103: 889-96.
 [http://dx.doi.org/10.1016/j.biopha.2018.04.117] [PMID:  29710505]

[10]
Stockwin LH. Alveolar soft-part sarcoma (ASPS) resembles a mesenchymal stromal progenitor: Evidence from meta-analysis of transcriptomic data. PeerJ  2020; 8: e9394.
 [http://dx.doi.org/10.7717/peerj.9394] [PMID:  32596059]

[11]
Paoluzzi L, Maki RG. Diagnosis, prognosis, and treatment of alveolar soft-part sarcoma. JAMA Oncol  2019; 5(2): 254-60.
 [http://dx.doi.org/10.1001/jamaoncol.2018.4490] [PMID:  30347044]

[12]
Falkenstern-Ge RF, Kimmich M, Wohlleber M, et al. Lung metastasis of primary alveolar soft-part sarcoma occurring 20 years after initial treatment. Case Rep Oncol Med  2013; 2013: 1-3.
 [http://dx.doi.org/10.1155/2013/690520] [PMID:  24379977]

[13]
Stockwin LH, Vistica DT, Kenney S, et al. Gene expression profiling of alveolar soft-part sarcoma (ASPS). BMC Cancer  2009; 9(1): 22.
 [http://dx.doi.org/10.1186/1471-2407-9-22] [PMID:  19146682]

[14]
Stacchiotti S, Negri T, Zaffaroni N, et al. Sunitinib in advanced alveolar soft part sarcoma: Evidence of a direct antitumor effect. Ann Oncol  2011; 22(7): 1682-90.
 [http://dx.doi.org/10.1093/annonc/mdq644] [PMID:  21242589]

[15]
Kummar S, Allen D, Monks A, et al. Cediranib for metastatic alveolar soft part sarcoma. J Clin Oncol  2013; 31(18): 2296-302.
 [http://dx.doi.org/10.1200/JCO.2012.47.4288] [PMID:  23630200]

[16]
Kim M, Kim TM, Keam B, et al. A phase II trial of pazopanib in patients with metastatic alveolar soft part sarcoma. Oncologist  2019; 24(1): 20-e29.
 [http://dx.doi.org/10.1634/theoncologist.2018-0464] [PMID:  30254189]

[17]
Schöffski P, Wozniak A, Kasper B, et al. Activity and safety of crizotinib in patients with alveolar soft part sarcoma with rearrangement of TFE3: European Organization for Research and Treatment of Cancer (EORTC) phase II trial 90101 ‘CREATE’. Ann Oncol  2018; 29(3): 758-65.
 [http://dx.doi.org/10.1093/annonc/mdx774] [PMID:  29216400]

[18]
Chi Y, Fang Z, Hong X, et al. Safety and efficacy of anlotinib, a multikinase angiogenesis inhibitor, in patients with refractory metastatic soft-tissue sarcoma. Clin Cancer Res  2018; 24(21): 5233-8.
 [http://dx.doi.org/10.1158/1078-0432.CCR-17-3766] [PMID:  29895706]

[19]
Xu Z, Zhang Y, Yu YH. Successful treatment of advanced alveolar soft part sarcoma with camrelizumab combined with apatinib: A case report. Ann Palliat Med  2021; 10(1): 785-92.
 [http://dx.doi.org/10.21037/apm-20-2275] [PMID:  33545800]

[20]
Pang JA, Yeung TF, Cockram CS. Alveolar soft-part sarcoma: A hormone-sensitive tumour? Postgrad Med J  1988; 64(751): 386-8.
 [http://dx.doi.org/10.1136/pgmj.64.751.386] [PMID:  3200782]

[21]
BaniHani MN. Al Manasra ARA. Spontaneous regression in alveolar soft part sarcoma: Case report and literature review. World J Surg Oncol  2009; 7(1): 53.
 [http://dx.doi.org/10.1186/1477-7819-7-53] [PMID:  19515237]

[22]
Vistica DT, Krosky PM, Kenney S, Raffeld M, Shoemaker RH. Immunohistochemical discrimination between the ASPL-TFE3 fusion proteins of alveolar soft part sarcoma. J Pediatr Hematol Oncol  2008; 30(1): 46-52.
 [http://dx.doi.org/10.1097/MPH.0b013e31815d1d6f] [PMID:  18176180]

[23]
Travis MA, Sheppard D. TGF-β activation and function in immunity. Annu Rev Immunol  2014; 32(1): 51-82.
 [http://dx.doi.org/10.1146/annurev-immunol-032713-120257] [PMID:  24313777]

[24]
Lazar AJF, Das P, Tuvin D, et al. Angiogenesis-promoting gene patterns in alveolar soft part sarcoma. Clin Cancer Res  2007; 13(24): 7314-21.
 [http://dx.doi.org/10.1158/1078-0432.CCR-07-0174] [PMID:  18094412]

[25]
Huan C, Kelly ML, Steele R, Shapira I, Gottesman SRS, Roman CAJ. Transcription factors TFE3 and TFEB are critical for CD40 ligand expression and thymus-dependent humoral immunity. Nat Immunol  2006; 7(10): 1082-91.
 [http://dx.doi.org/10.1038/ni1378] [PMID:  16936731]

[26]
Elgueta R, Benson MJ, de Vries VC, Wasiuk A, Guo Y, Noelle RJ. Molecular mechanism and function of CD40/CD40L engagement in the immune system. Immunol Rev  2009; 229(1): 152-72.
 [http://dx.doi.org/10.1111/j.1600-065X.2009.00782.x] [PMID:  19426221]

[27]
Samer Salah JHLSD, Anderson N, Periera SL, et al. Immunoprofiling in alveolar soft part sarcoma. J Clin Oncol  2017; 35: 11059.

[28]
Mittal A, Arun Raj ST, Gupta A, Shamim SA, Barwad A, Rastogi S. Letter to the editor: Immune checkpoint inhibitors in alveolar soft part sarcoma: New standard of care? J Adolesc Young Adult Oncol.   2021; 10: pp. (4)501-2.
 [http://dx.doi.org/10.1089/jayao.2020.0167] [PMID:  33326306]

[29]
Wilky BA, Trucco MM, Subhawong TK, et al. Axitinib plus pembrolizumab in patients with advanced sarcomas including alveolar soft-part sarcoma: A single-centre, single-arm, phase 2 trial. Lancet Oncol  2019; 20(6): 837-48.
 [http://dx.doi.org/10.1016/S1470-2045(19)30153-6] [PMID:  31078463]

[30]
Yang J, Dong L, Yang S, et al. Safety and clinical efficacy of toripalimab, a PD-1 mAb, in patients with advanced or recurrent malignancies in a phase I study. Eur J Cancer  2020; 130: 182-92.
 [http://dx.doi.org/10.1016/j.ejca.2020.01.028] [PMID:  32224416]

[31]
Tan Q, Wang D, Yang J, et al. Autoantibody profiling identifies predictive biomarkers of response to anti-PD1 therapy in cancer patients. Theranostics  2020; 10(14): 6399-410.
 [http://dx.doi.org/10.7150/thno.45816] [PMID:  32483460]

[32]
D’Angelo SP, Mahoney MR, Van Tine BA, et al. Nivolumab with or without ipilimumab treatment for metastatic sarcoma (Alliance A091401): Two open-label, non-comparative, randomised, phase 2 trials. Lancet Oncol  2018; 19(3): 416-26.
 [http://dx.doi.org/10.1016/S1470-2045(18)30006-8] [PMID:  29370992]

[33]
Groisberg R, Hong DS, Behrang A, et al. Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. J Immunother Cancer  2017; 5(1): 100.
 [http://dx.doi.org/10.1186/s40425-017-0301-y] [PMID:  29254498]

[34]
Mariuk-Jarema A, Koseła-Paterczyk H, Rogala P, et al. A durable complete response to immunotherapy in a patient with metastatic alveolar soft part sarcoma. Tumori  2020; 106(6): NP9-NP13.
 [http://dx.doi.org/10.1177/0300891620928133] [PMID:  32567515]

[35]
Dumbrava EI, Ivan D, Subbiah V. Hypopigmented skin lesions after immunotherapy. JAMA Oncol  2018; 4(8): 1118-9.
 [http://dx.doi.org/10.1001/jamaoncol.2018.0186] [PMID:  29801033]

[36]
Monga V, Skubitz KM, Maliske S, et al. A retrospective analysis of the efficacy of immunotherapy in metastatic soft-tissue sarcomas. Cancers (Basel)  2020; 12(7): 1873.
 [http://dx.doi.org/10.3390/cancers12071873] [PMID:  32664595]

[37]
Vander Jagt TA, Davis LE, Thakur MD, Franz C, Pollock JM. Pseudoprogression of CNS metastatic disease of alveolar soft part sarcoma during anti-PDL1 treatment. Radiol Case Rep  2018; 13(4): 882-5.
 [http://dx.doi.org/10.1016/j.radcr.2018.05.013] [PMID:  29991973]

[38]
Lewin J, Davidson S, Anderson ND, et al. Response to immune checkpoint inhibition in two patients with alveolar soft-part sarcoma. Cancer Immunol Res  2018; 6(9): 1001-7.
 [http://dx.doi.org/10.1158/2326-6066.CIR-18-0037] [PMID:  30018044]

[39]
Coyne GO, Sharon E, Moore N, et al. Phase II study of atezolizumab in patients with alveolar soft part sarcoma. Connective Tissue Oncology Society Annual Meeting.  Rome, Italy. 2018; pp. 14-7.

[40]
Groisberg R, Roszik J, Conley AP, et al. Genomics, morphoproteomics, and treatment patterns of patients with alveolar soft part sarcoma and response to multiple experimental therapies. Mol Cancer Ther  2020; 19(5): 1165-72.
 [http://dx.doi.org/10.1158/1535-7163.MCT-19-0579] [PMID:  32127467]

[41]
Lee DH, Armanious M, Huang J, Jeong D, Druta M, Fradley MG. Case of pembrolizumab-induced myocarditis presenting as torsades de pointes with safe re-challenge. J Oncol Pharm Pract  2020; 26(6): 1544-8.
 [http://dx.doi.org/10.1177/1078155220904152] [PMID:  32089073]

[42]
Broto JM, Hindi N, Redondo A, et al. Immunosarc: A collaborative Spanish (GEIS) and Italian (ISG) sarcoma groups phase I/II trial of sunitinib plus nivolumab in selected bone and soft tissue sarcoma subtypes—results of the phase I part. J Clin Oncol  2018; 36: 11515.

[43]
Paoluzzi L, Cacavio A, Ghesani M, et al. Response to anti-PD1 therapy with nivolumab in metastatic sarcomas. Clin Sarcoma Res  2016; 6(1): 24.
 [http://dx.doi.org/10.1186/s13569-016-0064-0] [PMID:  28042471]

[44]
Conley AP, Trinh VA, Zobniw CM, et al. Positive tumor response to combined checkpoint inhibitors in a patient with refractory alveolar soft part sarcoma: A case report. J Glob Oncol  2018; 4(4): 1-6.
 [http://dx.doi.org/10.1200/JGO.2017.009993] [PMID:  30241159]

[45]
Conry A, Peters M, Fried DB, et al. Complete response to dual immunotherapy in a young adult with metastatic alveolar soft part sarcoma enabled by a drug recovery program in a community practice. J Adolesc Young Adult Oncol  2020; 9(3): 449-52.
 [http://dx.doi.org/10.1089/jayao.2019.0113] [PMID:  31855495]

[46]
Zhao P, Li L, Jiang X, Li Q. Mismatch repair deficiency/microsatellite instability-high as a predictor for anti-PD-1/PD-L1 immunotherapy efficacy. J Hematol Oncol  2019; 12(1): 54.
 [http://dx.doi.org/10.1186/s13045-019-0738-1] [PMID:  31151482]

[47]
Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med  2016; 375(19): 1823-33.
 [http://dx.doi.org/10.1056/NEJMoa1606774] [PMID:  27718847]

[48]
D’Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol  2015; 46(3): 357-65.
 [http://dx.doi.org/10.1016/j.humpath.2014.11.001] [PMID:  25540867]

[49]
Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1-positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One  2013; 8(12): e82870.
 [http://dx.doi.org/10.1371/journal.pone.0082870] [PMID:  24349382]

[50]
Rotz SJ, Leino D, Szabo S, Mangino JL, Turpin BK, Pressey JG. Severe cytokine release syndrome in a patient receiving PD-1-directed therapy. Pediatr Blood Cancer  2017; 64(12): e26642.
 [http://dx.doi.org/10.1002/pbc.26642] [PMID:  28544595]

[51]
Tawbi HA, Burgess M, Bolejack V, et al. Pembrolizumab in advanced soft-tissue sarcoma and bone sarcoma (SARC028): A multicentre, two-cohort, single-arm, open-label, phase 2 trial. Lancet Oncol  2017; 18(11): 1493-501.
 [http://dx.doi.org/10.1016/S1470-2045(17)30624-1] [PMID:  28988646]

[52]
Callahan MK, Postow MA, Wolchok JD. CTLA-4 and PD-1 pathway blockade: Combinations in the clinic. Front Oncol  2015; 4: 385.
 [PMID:  25642417]

[53]
Roulleaux Dugage M, Nassif EF, Italiano A, Bahleda R. Improving immunotherapy efficacy in soft-tissue sarcomas: A biomarker driven and histotype tailored review. Front Immunol  2021; 12: 775761.
 [http://dx.doi.org/10.3389/fimmu.2021.775761] [PMID:  34925348]

[54]
Italiano A, Bellera C, D’Angelo S. PD1/PD-L1 targeting in advanced soft-tissue sarcomas: A pooled analysis of phase II trials. J Hematol Oncol  2020; 13(1): 55.
 [http://dx.doi.org/10.1186/s13045-020-00891-5] [PMID:  32430039]

[55]
Stacchiotti S, Tamborini E, Marrari A, et al. Response to sunitinib malate in advanced alveolar soft part sarcoma. Clin Cancer Res  2009; 15(3): 1096-104.
 [PMID:  19188185]

[56]
Judson I, Morden JP, Kilburn L, et al. Cediranib in patients with alveolar soft-part sarcoma (CASPS): A double-blind, placebo-controlled, randomised, phase 2 trial. Lancet Oncol  2019; 20(7): 1023-34.
 [http://dx.doi.org/10.1016/S1470-2045(19)30215-3] [PMID:  31160249]

[57]
Yang J, Yan J, Liu B. Targeting VEGF/VEGFR to modulateantitumor immunity. Front Immunol  2018; 9: 978.
 [http://dx.doi.org/10.3389/fimmu.2018.00978] [PMID:  29774034]

Rights & Permissions Print Cite

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/1381612828666220921151750	Print ISSN 1381-6128
Publisher Name Bentham Science Publisher	Online ISSN 1873-4286

Current Pharmaceutical Design

Comparative Combinatorial Implications and Theranostics of Immunotherapy in the Impediment of Alveolar Soft Part Sarcoma

Abstract Play Pause

Related Journals

Related Books

Abstract